论文部分内容阅读
The RAS-RAF-MEK-ERK signaling pathway plays an important role in normal cell biological process.In clinical,more than 30%human cancers harbor aberrant or hyper-activation of ERK pathway by receptor level(e.g.,EGFR,HER2 or FLT-3)or RAS,BRAF mutations[1].MEK1/2 kinases which are downstream effectors of the ERK pathway are considered as the important targets for cancer drug development[2].